Your Source for Venture Capital and Private Equity Financings

Navigator Medicines Raises $100M Series A

2024-08-27
SCOTCH PLAINS, NJ, Navigator Medicines today announced a $100 million Series A financing round.
Navigator Medicines, a privately-held biotech company leading the advancement of biologics for targeted immune regulation and restoration, today announced a Series A financing alongside the in-licensing of NAV-240 and an OX40L-targeted portfolio from IMBiologics Corp.

The $100 million Series A financing was co-led by RA Capital Management and Forbion.

Navigator Medicines is a biotech company leading the advancement of biologics for targeted immune regulation & restoration. Founded in 2024 as a subsidiary of Sera Medicines, the Company is committed to developing new therapies for patients living with complex, heterogeneous autoimmune diseases.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors